Axsome Therapeutics, Inc. remains a Sell due to an undifferentiated CNS pipeline, heavy SG&A and net losses. Learn more about ...

Of course, there are countless value stocks that are worth mentioning, but this is a concise list of the top 3 undervalued ...

On Stumble, Arianna Davis plays narcoleptic cheerleader Madonna, who often passes out while performing. Learn more about the ...

Narcolepsy type 1 is a chronic, rare neurological disease caused by the loss of orexin neurons in the brain. Orexin is a ...

Alixorexton’s Phase II performance sets it up for late-stage success, according to analysts at Truist Securities. Alkermes ...

Alkermes plc’s placebo-controlled phase II study of alixorexton in treating narcolepsy type 2 (NT2) hit its dual primary endpoints, producing statistically significant and clinically meaningful ...

As a comedy writer and person living with narcolepsy, I can tell you — there's nothing funny about it,' writes an L.A. Times reader.

Narcolepsy was not associated with increased mortality risk compared to not having the condition, even among patients with psychiatric comorbidities, a new retrospective cohort study showed. The ...

However, even in a market with generic competitors, Xywav offers a differentiated profile, and we will partner with payers to ...

Alkermes' experimental drug significantly improved wakefulness and reduced excessive sleepiness in patients with a rare sleep disorder in a mid-stage study, it said on Wednesday. The company was ...

On Wednesday, Alkermes plc (NASDAQ:ALKS) agreed to acquire Avadel Pharmaceuticals plc (NASDAQ:AVDL) for up to $20 per share in cash, which values Avadel at approximately $2.1 billion. The deal ...